Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05593367

Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients

Diarrhea-predominant Irritable Bowel Syndrome Clinical Trial

Official title:
Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Clinical Trial Summary

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease. Evidence suggests that the concentration of serum VD is decreased in IBS patients, particularly in IBS-D. After giving a supplementation of VD, some symptoms of these patients were relieved to a certain degree. However, the specific mechanism still remains unclear.

Clinical Trial Description

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease, which is due to the gut microbiota disturbances, intestinal mucosal barrier dysfunction, and brain-gut axis dysfunction. Vitamin D (VD), a fat-soluble vitamin, has been found to be associated with gut microbiota, intestinal mucosal barrier and NLRP3 in inflammatory bowel disease, nonalcoholic fatty liver disease and other diseases. The concentration of serum VD is decreased in IBS patients, particularly in IBS-D. And the symptoms of IBS patients seems to be connected with the level of serum VD. After giving a supplementation of VD, some symptoms of these patients were relieved to a certain degree. However, the specific mechanism still remains unclear.We designed a study to figure out the effects of serum VD on gut microbiota, intestinal mucosal barrier and in patients with IBS-D. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05593367
Study type Observational
Source Second Affiliated Hospital of Xi'an Jiaotong University
Contact Fei Dai
Phone 13772151298
Email daifei68@hotmail.com
Status Recruiting
Phase
Start date February 1, 2022
Completion date June 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04095988 - Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) N/A
Completed NCT01736423 - A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome Phase 3
Completed NCT02612649 - Special Drug Use Surveillance of Irribow in Female Patients
Completed NCT01414244 - Glutamine for the Treatment of Patients With Irritable Bowel Syndrome Phase 2
Completed NCT03977155 - Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT02163213 - Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D N/A
Terminated NCT01358708 - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg Phase 3
Not yet recruiting NCT06346847 - Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS N/A
Not yet recruiting NCT05687435 - Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2/Phase 3
Completed NCT01870895 - A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) Phase 3
Completed NCT02538692 - Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Phase 2/Phase 3
Completed NCT03099785 - Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Phase 2
Recruiting NCT05369884 - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D Early Phase 1
Completed NCT01350570 - Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial Phase 2/Phase 3